Education · Tier 4
· Last Reviewed May 12, 2026· PSI Editorial Board· IndependentWhat Bloodwork Is Required for Osteoporosis Peptide Therapy?
The honest reference for anabolic osteoporosis peptide baseline bloodwork across teriparatide, abaloparatide, and romosozumab therapy, anchored in FDA labels plus AACE/ACE 2020 and Endocrine Society 2019 CPGs.
Anabolic osteoporosis peptide therapy requires baseline calcium, vitamin D, PTH, creatinine, and bone turnover markers.
The FDA labels for Forteo, Tymlos, and Evenity specify the framework.
AACE/ACE 2020 and Endocrine Society 2019 CPGs anchor monitoring.
Evenity adds cardiovascular risk stratification per the FDA boxed warning.
Quick Answer
Anabolic osteoporosis peptide therapy with Forteo, Tymlos, and Evenity requires comprehensive mineral metabolism baseline. The framework anchors in AACE/ACE 2020 and Endocrine Society 2019 CPGs.
For Teriparatide (Forteo NDA 021318) and abaloparatide (Tymlos), baseline includes calcium, vitamin D, PTH, creatinine, CTX, and P1NP. Hypercalcemia contraindicates PTH analog therapy.
For Romosozumab (Evenity NDA 761062), baseline includes the same mineral metabolism panel. Evenity adds cardiovascular risk stratification per the FDA boxed warning. The warning excludes patients with MI or stroke within 12 months.
The bone turnover markers CTX and P1NP anchor treatment response monitoring. P1NP rises significantly with teriparatide and abaloparatide as the early biomarker.
Baseline DEXA bone mineral density and FRAX fracture risk score establish the indication threshold. The framework supports high fracture risk osteoporosis indication.
Monitoring follows a four-stage cadence. The stages are baseline at week 0, early follow-up at month 1, and stabilization at month 3. The maintenance stage is at month 6 with annual continuation. See Bloodwork Before Peptide Therapy for the full framework. For prescription context, see Compounded vs FDA-Approved.
The baseline framework spans mineral metabolism plus bone turnover markers. Total calcium with albumin correction establishes baseline. Hypercalcemia contraindicates PTH analog therapy with Forteo or Tymlos. The 25-hydroxy vitamin D establishes adequacy with supplementation typically required pre-initiation. Parathyroid hormone supports primary hyperparathyroidism exclusion. Creatinine establishes kidney function baseline. CTX is the bone resorption marker. P1NP is the bone formation marker. P1NP rises significantly with teriparatide and abaloparatide as the early biomarker. Evenity adds cardiovascular risk stratification per the FDA boxed warning April 2019.
OSTEOPOROSIS PEPTIDE BLOODWORK
At a Glance: Bloodwork for Osteoporosis Peptide Therapy
| Marker / Test | Subtitle | Animal Evidence | Human Evidence | Clinical Rationale |
|---|---|---|---|---|
| Total calcium with albumin correction | Mineral baseline plus PTH analog contraindication screening | — | Strong | Hypercalcemia contraindicates PTH analog therapy with Forteo or Tymlos per FDA labels |
| 25-hydroxy vitamin D baseline | Vitamin D adequacy before bone-forming peptide initiation | — | Strong | Supplementation typically required pre-initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs |
| Parathyroid hormone (PTH) baseline | Primary hyperparathyroidism exclusion before therapy | — | Strong | Baseline PTH supports differential diagnosis and contraindication screening |
| Creatinine baseline | Kidney function plus 24-hour urinary calcium as indicated | — | Strong | Creatinine establishes kidney function. Severe renal impairment caution applies per FDA labels |
| C-terminal telopeptide (CTX) | Bone resorption marker baseline | — | Strong | CTX establishes ongoing comparison for treatment response per Endocrine Society 2019 CPG |
| Procollagen type 1 N-terminal propeptide (P1NP) | Bone formation marker and early biomarker for treatment response | — | Strong | P1NP rises significantly with teriparatide and abaloparatide as the early biomarker |
| Cardiovascular risk stratification (Evenity-specific) | FDA boxed warning compliance screening | — | Strong | Contraindicated in MI or stroke within 12 months per FDA boxed warning April 2019 |
| DEXA plus FRAX score | Indication threshold for high fracture risk osteoporosis | — | Strong | Bone mineral density via DEXA plus FRAX score establish indication per CPGs |
Six Things You Need to Know About Osteoporosis Peptide Bloodwork
This page covers anabolic osteoporosis peptide baseline bloodwork in detail. The framework spans the FDA-approved bone-forming peptide class. Section one covers PTH analog therapy with Forteo and Tymlos. Section two covers romosozumab therapy with Evenity. Section three covers bone turnover marker monitoring. Section four covers the cardiovascular boxed warning for Evenity.
Total Calcium Establishes Baseline and Screens for PTH Analog Contraindication
Total calcium with albumin correction is the foundational baseline marker. Hypercalcemia is a contraindication to PTH analog therapy with teriparatide (Forteo) and abaloparatide (Tymlos) per FDA prescribing information.
The FDA prescribing information for Forteo (teriparatide, NDA 021318) lists pre-existing hypercalcemia as a contraindication. Tymlos (abaloparatide) lists the same contraindication. The mechanism is that PTH analog therapy stimulates osteoblast activity and can transiently increase serum calcium. For patients with pre-existing hypercalcemia, additional elevation poses risk. Baseline total calcium with albumin correction supports contraindication screening. For elevated baseline calcium, additional evaluation for primary hyperparathyroidism, malignancy, or other causes is required before therapy initiation. The AACE/ACE 2020 Postmenopausal Osteoporosis CPG (Camacho et al.) and Endocrine Society 2019 CPG (Eastell et al.) anchor the framework. Monitoring intervals follow FDA prescribing information with calcium re-check at month 1, month 3, month 6, and annual continuation thereafter.
Vitamin D Adequacy Is Required Before Bone-Forming Peptide Initiation
Baseline 25-hydroxy vitamin D establishes adequacy. Vitamin D supplementation is typically required pre-initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs.
Vitamin D adequacy is foundational to bone health. The AACE/ACE 2020 CPG specifies 25-OH vitamin D level above 30 ng/mL as adequate before anabolic peptide therapy initiation. Endocrine Society 2019 CPG provides comparable guidance. Vitamin D supplementation (typically vitamin D3 cholecalciferol) is required before initiation for patients with insufficient or deficient baseline levels. The mechanism is that vitamin D supports intestinal calcium absorption required for the anabolic bone formation response to teriparatide, abaloparatide, and romosozumab. Without adequate vitamin D, the bone formation response is suboptimal. Monitoring intervals follow CPG guidance with 25-OH vitamin D re-check at month 3 stabilization and annual continuation thereafter. Specialty coordination with endocrinology supports complex evaluation when vitamin D deficiency is severe or refractory.
PTH Baseline Excludes Primary Hyperparathyroidism Before Therapy
Baseline parathyroid hormone (PTH) supports primary hyperparathyroidism exclusion. Primary hyperparathyroidism with elevated calcium contraindicates PTH analog therapy.
Primary hyperparathyroidism is a clinical entity characterized by elevated PTH plus elevated calcium. The condition is a differential diagnosis for osteoporosis and may explain bone loss without requiring anabolic peptide therapy. Baseline PTH establishes the framework for differential diagnosis. Elevated baseline PTH with elevated calcium suggests primary hyperparathyroidism requiring endocrinology evaluation before any anabolic peptide therapy decision. Elevated PTH with normal calcium may suggest secondary hyperparathyroidism due to vitamin D deficiency, kidney disease, or other causes requiring evaluation and treatment before bone-forming peptide initiation. AACE/ACE 2020 and Endocrine Society 2019 CPGs anchor the framework. Specialty coordination with endocrinology applies for complex parathyroid evaluation. Monitoring intervals include PTH re-check at annual continuation thereafter.
Bone Turnover Markers CTX and P1NP Anchor Treatment Response
Bone turnover markers CTX and P1NP anchor treatment response monitoring per Endocrine Society 2019 and AACE/ACE 2020 CPGs. P1NP rises significantly with teriparatide and abaloparatide as the early biomarker.
Bone turnover markers provide validated biomarkers for treatment response. CTX is the bone resorption marker reflecting osteoclast activity and bone breakdown. P1NP is the bone formation marker reflecting osteoblast activity and bone formation. PTH analog therapy with teriparatide and abaloparatide stimulates osteoblast activity and increases bone formation. P1NP rises significantly within weeks of therapy initiation and serves as the early biomarker for treatment response. The VERT trial (Neer et al. NEJM 2001) established teriparatide vertebral fracture reduction. The ACTIVE trial (Miller et al. JAMA 2016) established abaloparatide fracture reduction. Romosozumab (Evenity) uniquely dual-modulates bone: it increases formation (P1NP rise) while simultaneously decreasing resorption (CTX decrease). The FRAME trial (Cosman et al. NEJM 2016) and ARCH trial (Saag et al. NEJM 2017) established romosozumab efficacy. Monitoring intervals follow Endocrine Society 2019 guidance with CTX and P1NP at baseline, month 3, and month 6 stabilization stage.
Evenity Adds Cardiovascular Risk Stratification per FDA Boxed Warning
Romosozumab (Evenity, NDA 761062) carries an FDA cardiovascular boxed warning issued April 2019. Baseline cardiovascular risk stratification is required including MI history, stroke history, and cardiovascular risk factor assessment.
The FDA cardiovascular boxed warning for Evenity was issued April 2019 based on the ARCH trial (Saag et al. NEJM 2017). The ARCH trial compared romosozumab plus alendronate versus alendronate alone over 36 months. The trial demonstrated superior fracture reduction with the romosozumab arm but also showed a numerical excess of serious cardiovascular events (myocardial infarction, stroke, cardiovascular death) in the romosozumab arm. The boxed warning specifies contraindication in patients with myocardial infarction or stroke within the previous 12 months. The warning specifies caution and individualized clinical evaluation for patients with established cardiovascular disease, multiple cardiovascular risk factors, or prior cardiovascular events outside the 12-month window. Baseline cardiovascular risk stratification includes history of MI, stroke, peripheral arterial disease, heart failure, hypertension, diabetes, and lipid status. Specialty coordination with cardiology applies for complex cardiovascular contexts. Monitoring intervals include cardiovascular event surveillance across the 12-month therapy course.
Four-Stage Monitoring Cadence Anchors Continuous Quality Care
Monitoring follows a four-stage cadence: baseline at week 0, early follow-up at month 1, stabilization at month 3, and maintenance at month 6 with annual continuation.
Stage 1 baseline at week 0 establishes the full panel: total calcium with albumin correction, 25-OH vitamin D, parathyroid hormone, creatinine, CTX, P1NP, plus DEXA bone mineral density and FRAX score. For Evenity, cardiovascular risk stratification is added. Stage 2 early follow-up at month 1 tracks calcium response, dose tolerability, and treatment initiation tolerability. Stage 3 stabilization at month 3 captures bone turnover marker response: P1NP rise indicating osteoblast stimulation for Forteo and Tymlos, plus CTX response. Vitamin D and calcium re-check applies at stabilization. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check including DEXA at year 1 or year 2 per AACE/ACE 2020 CPG guidance. The Forteo and Tymlos therapy duration is generally limited to 24 months lifetime per FDA labels due to osteosarcoma boxed warning. Evenity therapy duration is generally limited to 12 monthly doses per FDA label. Adverse event reporting through FDA MedWatch applies for serious events.
Lab Panels by Context
Forteo and Tymlos PTH Analog Baseline Panel
Anabolic osteoporosis peptide (PTH analog) · applies to: teriparatide (Forteo NDA 021318), abaloparatide (Tymlos)
PTH analog therapy requires comprehensive mineral metabolism baseline plus bone turnover markers. Hypercalcemia contraindicates therapy per FDA labels. Vitamin D adequacy is required pre-initiation per AACE/ACE 2020 CPG.
Context: FDA-approved PTH 1-34 (teriparatide) and PTHrP analog (abaloparatide) for high fracture risk osteoporosis. Lifetime therapy duration limit of generally 24 months per FDA labels.
| Test | Why ordered | Monitoring |
|---|---|---|
| Total calcium with albumin correction | Mineral metabolism baseline plus hypercalcemia contraindication screening. Hypercalcemia contraindicates PTH analog therapy per FDA labels. | baseline, month 1, month 3, month 6, annual |
| 25-hydroxy vitamin D | Vitamin D adequacy baseline. Supplementation typically required pre-initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs. | baseline, month 3, annual |
| Parathyroid hormone (PTH) | Primary hyperparathyroidism exclusion before PTH analog therapy. Baseline PTH supports differential diagnosis including secondary hyperparathyroidism. | baseline, annual |
| Creatinine and 24-hour urinary calcium | Kidney function baseline plus urinary calcium for nephrolithiasis risk assessment. Severe renal impairment caution applies per FDA labels. | baseline, month 6, annual |
| C-terminal telopeptide (CTX) | Bone resorption marker baseline establishing ongoing comparison for treatment response. CTX rises moderately with PTH analog therapy. | baseline, month 3, month 6 |
| Procollagen type 1 N-terminal propeptide (P1NP) | Bone formation marker and early biomarker for treatment response. P1NP rises significantly with teriparatide and abaloparatide therapy within 4-8 weeks. | baseline, month 3, month 6 |
Evenity Romosozumab Baseline Panel (with Cardiovascular Boxed Warning)
Anabolic osteoporosis peptide (sclerostin inhibitor) · applies to: romosozumab (Evenity NDA 761062)
Romosozumab dual-modulates bone and requires the same mineral metabolism baseline plus cardiovascular risk stratification per the FDA boxed warning issued April 2019.
Context: FDA-approved sclerostin inhibitor for postmenopausal osteoporosis at high fracture risk. Therapy duration limit of 12 monthly doses per FDA label.
| Test | Why ordered | Monitoring |
|---|---|---|
| Total calcium with albumin correction | Mineral metabolism baseline. Hypocalcemia must be corrected before romosozumab initiation per FDA label. | baseline, month 1, month 3, month 6 |
| 25-hydroxy vitamin D | Vitamin D adequacy baseline. Supplementation typically required pre-initiation per AACE/ACE 2020 CPG. | baseline, month 3, month 6 |
| Parathyroid hormone (PTH) | Differential diagnosis support including secondary hyperparathyroidism from vitamin D deficiency. | baseline |
| Creatinine | Kidney function baseline. Severe renal impairment requires individualized evaluation per FDA label. | baseline, month 6 |
| Cardiovascular risk stratification (MI, stroke, CV disease history) | FDA cardiovascular boxed warning issued April 2019. Contraindicated in patients with MI or stroke within 12 months per FDA label. | baseline, monthly across 12-month course |
| C-terminal telopeptide (CTX) | Bone resorption marker baseline. CTX decreases significantly with romosozumab (osteoclast inhibition, unique dual-modulation signature). | baseline, month 3, month 6 |
| Procollagen type 1 N-terminal propeptide (P1NP) | Bone formation marker. P1NP rises significantly with romosozumab (osteoblast stimulation via sclerostin inhibition). | baseline, month 3, month 6 |
Sequential Anti-Resorptive Maintenance Panel
Sequential framework after anabolic course completion · applies to: all anabolic osteoporosis peptide therapy completers (Forteo, Tymlos, Evenity)
Sequential anti-resorptive therapy with bisphosphonate or denosumab is required after anabolic course completion per AACE/ACE 2020 CPG to maintain bone density gains.
Context: Mandatory sequential framework. Without sequential anti-resorptive therapy, bone density gains achieved during the anabolic course are rapidly lost.
| Test | Why ordered | Monitoring |
|---|---|---|
| DEXA bone mineral density (sequential transition timing) | Baseline DEXA at sequential transition point captures bone density gain achieved during anabolic course. Subsequent DEXA at year 2 monitors maintenance. | sequential transition, year 2 |
| Total calcium and 25-OH vitamin D (sequential) | Mineral metabolism baseline before sequential anti-resorptive initiation. Supplementation continuation as appropriate. | sequential transition, annual |
| CTX and P1NP (sequential transition) | Bone turnover marker baseline before sequential anti-resorptive initiation. CTX suppression with bisphosphonate or denosumab confirms anti-resorptive response. | sequential transition, month 6 of anti-resorptive |
Teriparatide (Forteo) and abaloparatide (Tymlos): PTH analog framework
Baseline framework for PTH analog anabolic osteoporosis peptide therapy per FDA labels and CPGs
Teriparatide (Forteo, FDA-approved 2002, NDA 021318) is recombinant human PTH 1-34 administered as 20 mcg daily subcutaneous injection. Abaloparatide (Tymlos, FDA-approved 2017) is a synthetic analog of PTH-related protein administered as 80 mcg daily subcutaneous injection. Both drugs are PTH analog anabolic osteoporosis peptides that stimulate osteoblast activity and increase bone formation. Therapy duration is generally limited to 24 months lifetime per FDA labels due to osteosarcoma boxed warning based on rodent studies.
The baseline bloodwork framework is comparable for both drugs. It includes total calcium with albumin correction (hypercalcemia contraindicates therapy), 25-hydroxy vitamin D (supplementation required if deficient), parathyroid hormone (primary hyperparathyroidism exclusion), creatinine for kidney function, and bone turnover markers CTX (resorption) plus P1NP (formation). The AACE/ACE 2020 Postmenopausal Osteoporosis CPG (Camacho et al.) and Endocrine Society 2019 CPG (Eastell et al.) anchor the framework across both drugs.
The VERT trial (Neer et al. NEJM 2001) established teriparatide efficacy with 65 percent reduction in vertebral fractures and 53 percent reduction in non-vertebral fractures in postmenopausal osteoporosis. The ACTIVE trial (Miller et al. JAMA 2016) established abaloparatide efficacy with 86 percent reduction in vertebral fractures over 18 months. P1NP rises significantly within weeks of therapy initiation and serves as the early biomarker for treatment response per Endocrine Society 2019 CPG. Specialty coordination with endocrinology or rheumatology strengthens the framework.
Romosozumab (Evenity): dual-modulator framework with cardiovascular boxed warning
Baseline framework for romosozumab sclerostin inhibitor with FDA cardiovascular boxed warning
Romosozumab (Evenity, FDA-approved April 2019, NDA 761062) is a humanized monoclonal antibody that binds and inhibits sclerostin. Romosozumab uniquely dual-modulates bone: it increases bone formation (osteoblast stimulation) while simultaneously decreasing bone resorption (osteoclast inhibition). The dosing is 210 mg monthly subcutaneous injection for 12 months. Therapy duration is generally limited to 12 monthly doses per FDA label.
The baseline bloodwork framework includes the same mineral metabolism panel: total calcium, 25-OH vitamin D, PTH, creatinine. Bone turnover markers CTX and P1NP anchor treatment response with romosozumab showing P1NP rise plus CTX decrease (the dual modulation signature). The FDA cardiovascular boxed warning was issued April 2019 based on the ARCH trial (Saag et al. NEJM 2017) showing numerical excess of serious cardiovascular events in the romosozumab arm.
Baseline cardiovascular risk stratification is required including MI history, stroke history, peripheral arterial disease history, heart failure history, hypertension, diabetes, and lipid status. Evenity is contraindicated in patients with MI or stroke within the previous 12 months. The FRAME trial (Cosman et al. NEJM 2016) demonstrated Evenity efficacy versus placebo with 73 percent reduction in vertebral fractures over 12 months. Specialty coordination with cardiology applies for complex cardiovascular contexts including patients with established cardiovascular disease outside the 12-month exclusion window.
Bone turnover markers CTX and P1NP: validated treatment response biomarkers
Bone resorption and formation marker framework per Endocrine Society 2019 and AACE/ACE 2020 CPGs
Bone turnover markers provide validated biomarkers for treatment response assessment in anabolic osteoporosis peptide therapy. The two clinically relevant markers are C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP). CTX reflects bone resorption through osteoclast activity. P1NP reflects bone formation through osteoblast activity.
For PTH analog therapy with teriparatide and abaloparatide, P1NP rises significantly within 4 to 8 weeks of therapy initiation reflecting osteoblast stimulation. CTX rises moderately reflecting coupled bone turnover. The P1NP rise serves as the early biomarker for treatment response per Endocrine Society 2019 Pharmacological Management of Osteoporosis CPG (Eastell et al. JCEM).
For romosozumab, the bone turnover marker pattern is unique. P1NP rises significantly through osteoblast stimulation via sclerostin inhibition. CTX decreases through osteoclast inhibition. The dual modulation signature distinguishes romosozumab from PTH analogs. Specialty endocrinology and rheumatology routinely order CTX and P1NP for anabolic osteoporosis peptide treatment response monitoring. Monitoring intervals follow CPG guidance with markers at baseline, month 3, and month 6.
DEXA bone mineral density and FRAX fracture risk score: indication threshold
Indication threshold framework for high fracture risk osteoporosis peptide therapy
Baseline DEXA bone mineral density (BMD) is required before anabolic osteoporosis peptide therapy initiation. DEXA assesses BMD at the lumbar spine, femoral neck, and total hip. Osteoporosis is defined by T-score below -2.5 standard deviations from young adult reference per WHO criteria. Severe osteoporosis is defined by T-score below -2.5 plus prior fragility fracture. AACE/ACE 2020 CPG specifies anabolic peptide therapy for very high fracture risk including patients with very low BMD or recent fracture.
FRAX fracture risk score provides 10-year probability of major osteoporotic fracture and hip fracture. The score incorporates age, sex, BMI, prior fracture, parental hip fracture, smoking, alcohol use, corticosteroid use, rheumatoid arthritis, secondary osteoporosis causes, and BMD. AACE/ACE 2020 CPG specifies anabolic peptide therapy for FRAX major osteoporotic fracture probability above 20 percent or hip fracture probability above 3 percent.
The indication threshold for anabolic osteoporosis peptide therapy is high fracture risk osteoporosis per FDA labels and society CPGs. The framework supports decisions for postmenopausal women at very high fracture risk, men with high fracture risk osteoporosis where labeled, and patients with glucocorticoid-induced osteoporosis for Forteo per FDA label. Specialty coordination with endocrinology or rheumatology strengthens the framework. Monitoring includes DEXA at year 1 or year 2 per CPG guidance with FRAX recalculation.
Research Suggests
Direction
Anabolic osteoporosis peptide therapy baseline bloodwork follows FDA prescribing information plus AACE/ACE 2020 and Endocrine Society 2019 CPGs across the bone-forming peptide class.
The framework spans six foundational markers: total calcium with albumin correction, 25-OH vitamin D, parathyroid hormone, creatinine, C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). Plus DEXA bone mineral density and FRAX fracture risk score for indication threshold. For Evenity specifically, cardiovascular risk stratification adds per the FDA boxed warning. The framework applies across teriparatide (Forteo NDA 021318), abaloparatide (Tymlos), and romosozumab (Evenity NDA 761062). Anchored in AACE/ACE 2020 (Camacho et al.), Endocrine Society 2019 (Eastell et al.), VERT 2001, ACTIVE 2016, FRAME 2016, ARCH 2017, and FDA cardiovascular boxed warning April 2019.
Strongest evidence
Mineral metabolism baseline plus bone turnover markers have the strongest evidence anchoring across the class.
Calcium baseline is anchored in FDA prescribing information across PTH analog therapy with hypercalcemia listed as contraindication. Vitamin D adequacy is anchored in AACE/ACE 2020 and Endocrine Society 2019 CPGs with supplementation required pre-initiation. PTH baseline supports primary hyperparathyroidism exclusion per CPG guidance. Bone turnover markers CTX and P1NP are validated treatment response biomarkers per Endocrine Society 2019 CPG. The VERT trial (Neer et al. NEJM 2001) established teriparatide efficacy. The ACTIVE trial (Miller et al. JAMA 2016) established abaloparatide efficacy. The FRAME trial (Cosman et al. NEJM 2016) and ARCH trial (Saag et al. NEJM 2017) established romosozumab efficacy and cardiovascular safety signal.
Limitations
Evenity adds cardiovascular risk stratification per the FDA boxed warning issued April 2019. Therapy duration limits apply per FDA labels.
Evenity cardiovascular boxed warning excludes patients with myocardial infarction or stroke within the previous 12 months. Patients with established cardiovascular disease, multiple cardiovascular risk factors, or prior cardiovascular events outside the 12-month window require individualized clinical evaluation per FDA label and specialty coordination with cardiology. PTH analog therapy with Forteo and Tymlos carries an osteosarcoma boxed warning based on rodent studies. Therapy duration is generally limited to 24 months lifetime per FDA labels. Romosozumab therapy duration is generally limited to 12 monthly doses per FDA label. Sequential therapy framework with anti-resorptive maintenance after anabolic course completion follows AACE/ACE 2020 CPG guidance.
Assessment
The framework establishes anabolic osteoporosis peptide baseline across teriparatide, abaloparatide, and romosozumab pathways.
PSI's reading: anabolic osteoporosis peptide baseline bloodwork is well-standardized across the FDA-approved class. The six foundational markers (calcium, vitamin D, PTH, creatinine, CTX, P1NP) apply uniformly. The DEXA plus FRAX indication threshold framework is consistent across the class. For Evenity, the cardiovascular boxed warning adds risk stratification requirements. AACE/ACE 2020 CPG (Camacho et al.) and Endocrine Society 2019 CPG (Eastell et al.) anchor the framework with comparable guidance. The four-stage monitoring cadence applies with bone turnover marker re-check at month 3 and month 6. P1NP rise serves as the early biomarker for treatment response across the class with the unique romosozumab signature of P1NP rise plus CTX decrease. Specialty coordination with endocrinology or rheumatology supports the framework. The PSI physician directory provides verified physicians ordering comprehensive osteoporosis peptide bloodwork across primary care, endocrinology, rheumatology, and other relevant specialties.
How to Approach Your Decision
- For Forteo or Tymlos PTH analog therapy, expect baseline calcium, vitamin D, PTH, creatinine, plus CTX and P1NP.
- For Evenity romosozumab therapy, expect the same mineral panel plus cardiovascular risk stratification.
- For patients with hypercalcemia at baseline, PTH analog therapy with Forteo or Tymlos is contraindicated.
- For patients with MI or stroke within 12 months, Evenity is contraindicated per FDA boxed warning.
- For patients with vitamin D deficiency, expect supplementation before anabolic peptide therapy initiation.
- For patients with established cardiovascular disease, expect cardiology coordination before Evenity therapy.
- Expect bone turnover marker re-check at month 3 with P1NP rise as early biomarker.
- Expect DEXA bone mineral density and FRAX score at baseline to confirm high fracture risk indication.
Limitations and Caveats
- Hypercalcemia at baseline contraindicates PTH analog therapy. Forteo and Tymlos cannot be used in patients with pre-existing hypercalcemia per FDA labels.
- Evenity is contraindicated within 12 months of MI or stroke. The FDA cardiovascular boxed warning issued April 2019 specifies the exclusion window.
- PTH analog therapy duration is limited to 24 months lifetime. Forteo and Tymlos labels specify the lifetime limit due to osteosarcoma boxed warning in rodent studies.
- Romosozumab therapy duration is limited to 12 monthly doses. Evenity label specifies the duration limit.
- Sequential anti-resorptive therapy is required after anabolic course completion. AACE/ACE 2020 CPG specifies bisphosphonate or denosumab maintenance after anabolic peptide therapy.
- Vitamin D adequacy is required before therapy initiation. Supplementation typically required pre-initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs.
- Specialty coordination strengthens the framework. Complex evaluation including primary hyperparathyroidism exclusion or cardiovascular assessment benefits from specialty input.
- Bone turnover marker monitoring requires consistent timing. Same morning, fasting status, and assay platform support reliable trend interpretation per Endocrine Society 2019 CPG.
What's Marketed vs What's Studied
7 common claims, corrected.
“Anabolic osteoporosis peptide therapy can be initiated without DEXA bone mineral density.”
DEXA bone mineral density and FRAX fracture risk score establish the indication threshold for anabolic osteoporosis peptide therapy. AACE/ACE 2020 CPG specifies anabolic peptide therapy for very high fracture risk patients. Baseline DEXA is required for indication confirmation and ongoing comparison.
“Bone turnover markers are too research-grade for routine osteoporosis peptide monitoring.”
Bone turnover markers CTX and P1NP are clinically used per AACE/ACE 2020 and Endocrine Society 2019 CPGs. P1NP rises significantly with teriparatide and abaloparatide therapy and serves as the early biomarker for treatment response. Specialty endocrinology and rheumatology routinely order these markers.
“Evenity does not require cardiovascular workup before initiation.”
Evenity (romosozumab, NDA 761062) carries an FDA cardiovascular boxed warning issued April 2019 based on the ARCH trial. Baseline cardiovascular risk stratification is required including MI history, stroke history, and cardiovascular risk factor assessment. The boxed warning excludes patients with MI or stroke within 12 months.
“PTH analog therapy with Forteo or Tymlos can continue indefinitely.”
FDA labels for Forteo and Tymlos specify lifetime therapy duration limit of generally 24 months. The limit reflects the osteosarcoma boxed warning based on rodent studies. After anabolic course completion, sequential anti-resorptive therapy with bisphosphonate or denosumab is required per AACE/ACE 2020 CPG.
“Vitamin D supplementation is optional before bone-forming peptide therapy.”
Vitamin D adequacy is required before anabolic osteoporosis peptide therapy initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs. Supplementation is typically required pre-initiation for patients with insufficient or deficient baseline levels. Without adequate vitamin D, the bone formation response is suboptimal.
“Hypercalcemia is just a number that does not affect the prescribing decision.”
Pre-existing hypercalcemia is a contraindication to PTH analog therapy with Forteo and Tymlos per FDA prescribing information. Baseline calcium with albumin correction supports the contraindication screening. For elevated baseline calcium, additional evaluation for primary hyperparathyroidism, malignancy, or other causes is required before therapy initiation.
“Anabolic osteoporosis peptide therapy is the same as bisphosphonate therapy.”
Anabolic osteoporosis peptide therapy (Forteo, Tymlos, Evenity) stimulates bone formation. Bisphosphonate therapy (alendronate, risedronate) inhibits bone resorption. The mechanisms differ. AACE/ACE 2020 CPG specifies anabolic therapy for very high fracture risk patients with sequential anti-resorptive maintenance after the anabolic course.
Common Questions
What baseline bloodwork is required before Forteo or Tymlos therapy?
Baseline panel includes total calcium with albumin correction, 25-hydroxy vitamin D, parathyroid hormone (PTH), creatinine for kidney function, plus bone turnover markers CTX (resorption) and P1NP (formation). Hypercalcemia contraindicates PTH analog therapy. Vitamin D adequacy is required pre-initiation. Baseline DEXA bone mineral density and FRAX fracture risk score establish indication threshold.
What baseline bloodwork is required before Evenity therapy?
Baseline panel includes the same mineral metabolism markers as Forteo and Tymlos (calcium, vitamin D, PTH, creatinine, CTX, P1NP) plus cardiovascular risk stratification per the FDA cardiovascular boxed warning. The boxed warning excludes patients with MI or stroke within 12 months. Baseline DEXA bone mineral density and FRAX fracture risk score establish indication threshold.
Why is hypercalcemia a contraindication to PTH analog therapy?
PTH analog therapy with teriparatide (Forteo) and abaloparatide (Tymlos) stimulates osteoblast activity and can transiently increase serum calcium. For patients with pre-existing hypercalcemia, additional calcium elevation poses risk. The FDA prescribing information lists hypercalcemia as a contraindication. Baseline calcium with albumin correction supports contraindication screening.
Why does Evenity have a cardiovascular boxed warning?
The FDA cardiovascular boxed warning for Evenity was issued April 2019 based on the ARCH trial (Saag et al. NEJM 2017). The trial showed numerical excess of serious cardiovascular events (MI, stroke, cardiovascular death) in the romosozumab arm versus alendronate arm over 36 months. The boxed warning specifies contraindication in patients with MI or stroke within 12 months.
What are bone turnover markers CTX and P1NP?
CTX (C-terminal telopeptide) is the bone resorption marker reflecting osteoclast activity and bone breakdown. P1NP (procollagen type 1 N-terminal propeptide) is the bone formation marker reflecting osteoblast activity and bone formation. CTX and P1NP are validated treatment response biomarkers per Endocrine Society 2019 and AACE/ACE 2020 CPGs.
How does P1NP serve as the early biomarker for treatment response?
P1NP rises significantly within 4 to 8 weeks of PTH analog therapy initiation (Forteo, Tymlos) reflecting osteoblast stimulation. The P1NP rise serves as the early biomarker for treatment response per Endocrine Society 2019 CPG. For romosozumab (Evenity), P1NP rises while CTX decreases, the unique dual-modulation signature.
Why is vitamin D required before anabolic osteoporosis peptide therapy?
Vitamin D adequacy is required before anabolic osteoporosis peptide therapy initiation per AACE/ACE 2020 and Endocrine Society 2019 CPGs. Vitamin D supports intestinal calcium absorption required for the anabolic bone formation response. Supplementation is typically required pre-initiation for patients with insufficient or deficient baseline levels.
How long can I stay on Forteo or Tymlos?
FDA labels for Forteo (teriparatide) and Tymlos (abaloparatide) specify lifetime therapy duration limit of generally 24 months. The limit reflects the osteosarcoma boxed warning based on rodent studies. After anabolic course completion, sequential anti-resorptive therapy with bisphosphonate or denosumab is required per AACE/ACE 2020 CPG to maintain bone density gains.
How long can I stay on Evenity?
FDA label for Evenity (romosozumab) specifies therapy duration of 12 monthly doses. After the 12-month anabolic course, sequential anti-resorptive therapy with bisphosphonate or denosumab is required per AACE/ACE 2020 CPG. The 12-month limit reflects efficacy data plateau plus the cardiovascular safety signal from the ARCH trial.
Can my primary care physician order osteoporosis peptide baseline bloodwork?
Yes. Primary care can order baseline bloodwork for anabolic osteoporosis peptide therapy. For complex evaluation including primary hyperparathyroidism exclusion, severe vitamin D deficiency, or cardiovascular stratification for Evenity, specialty coordination with endocrinology, rheumatology, or cardiology strengthens the framework per AACE/ACE 2020 CPG.
Will my insurance cover osteoporosis peptide bloodwork?
Insurance coverage for osteoporosis peptide baseline bloodwork generally has prior authorization frameworks supporting the testing when the indication threshold is met. The threshold typically requires DEXA T-score below specific cutoff, prior fragility fracture, or FRAX score above specific threshold. Verify coverage with your insurance plan before the visit.
What if I have primary hyperparathyroidism?
Primary hyperparathyroidism (elevated PTH with elevated calcium) requires endocrinology evaluation and potentially parathyroidectomy before any anabolic peptide therapy consideration. The condition is a differential diagnosis for osteoporosis and may explain bone loss without requiring bone-forming peptide therapy. Baseline PTH supports the diagnostic workup.
What if I have a history of cardiovascular disease?
Patients with MI or stroke within 12 months are contraindicated from Evenity per FDA boxed warning. Patients with established cardiovascular disease outside the 12-month window require individualized clinical evaluation. Specialty coordination with cardiology applies for complex cardiovascular contexts. Forteo and Tymlos do not carry comparable cardiovascular contraindications.
What happens after my anabolic peptide therapy course completes?
Sequential anti-resorptive therapy with bisphosphonate (alendronate, zoledronic acid, risedronate) or denosumab is required after anabolic course completion per AACE/ACE 2020 CPG. The sequential framework maintains bone density gains achieved during the anabolic course. Without sequential therapy, bone density losses can occur rapidly.
Do I need DEXA bone mineral density before therapy?
Yes. Baseline DEXA is required before anabolic osteoporosis peptide therapy initiation. DEXA assesses bone mineral density at the lumbar spine, femoral neck, and total hip. The T-score establishes the indication threshold per WHO criteria and AACE/ACE 2020 CPG. Repeat DEXA at year 1 or year 2 monitors treatment response.
Can I get osteoporosis peptide bloodwork through telehealth?
Yes. Telehealth osteoporosis peptide bloodwork orders go through external laboratory networks like Quest Diagnostics, LabCorp, or local laboratory networks. The patient visits the laboratory for sample collection. DEXA bone mineral density requires in-person scan at a radiology center but can be coordinated with telehealth physician orders.
What if my bone turnover markers do not rise during therapy?
Inadequate bone turnover marker response (particularly P1NP failure to rise with PTH analog therapy) requires clinical evaluation for adherence, drug absorption, secondary causes of osteoporosis, or alternative therapy consideration. Specialty coordination with endocrinology supports the framework. Monitoring at month 3 captures the response window.
Where can I find a physician for osteoporosis peptide therapy?
The PSI physician directory provides verified physicians across major US cities including peptide therapy experience verification, state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice verification. The directory covers primary care, endocrinology, rheumatology, and women's health specialists for osteoporosis indications.
Evidence Ranking
Rank 1
Total calcium with albumin correction
Strongest evidence anchoring: FDA prescribing information across PTH analog therapy with hypercalcemia listed as contraindication per Forteo and Tymlos labels.
Rank 2
25-hydroxy vitamin D
Strong evidence anchoring: AACE/ACE 2020 and Endocrine Society 2019 CPGs specify supplementation required pre-initiation for adequate anabolic bone formation response.
Rank 3
Procollagen type 1 N-terminal propeptide (P1NP)
Strong evidence anchoring: Endocrine Society 2019 CPG validates P1NP as early biomarker for PTH analog and romosozumab treatment response.
Rank 4
C-terminal telopeptide (CTX)
Strong evidence anchoring: Endocrine Society 2019 CPG validates CTX as bone resorption marker. Distinguishes romosozumab dual-modulation signature (CTX decrease) from PTH analog pattern.
Rank 5
Parathyroid hormone (PTH)
Strong contextual anchoring: primary hyperparathyroidism exclusion before anabolic therapy per AACE/ACE 2020 CPG framework.
Rank 6
Cardiovascular risk stratification (Evenity-specific)
Strong contextual anchoring: FDA cardiovascular boxed warning April 2019 based on ARCH trial. Excludes MI or stroke within 12 months.
Sourcing Checklist
Order baseline bloodwork through prescribing physician with documented clinical interpretation.
Self-ordered direct-to-consumer bloodwork is not a substitute for physician-ordered baseline. AMA Code 1.1.5 informed consent requires physician clinical interpretation.
Confirm hypercalcemia exclusion before PTH analog therapy initiation.
Baseline total calcium with albumin correction supports contraindication screening for Forteo and Tymlos per FDA prescribing information.
Confirm vitamin D adequacy before bone-forming peptide initiation.
AACE/ACE 2020 and Endocrine Society 2019 CPGs specify supplementation typically required pre-initiation for patients with insufficient baseline 25-OH vitamin D levels.
Confirm primary hyperparathyroidism exclusion before anabolic therapy.
Elevated PTH with elevated calcium suggests primary hyperparathyroidism requiring endocrinology evaluation. Elevated PTH with normal calcium suggests secondary causes.
For Evenity specifically, confirm cardiovascular risk stratification at baseline.
The FDA cardiovascular boxed warning excludes patients with MI or stroke within 12 months. Established cardiovascular disease requires individualized cardiology evaluation.
Confirm DEXA bone mineral density and FRAX score establish high fracture risk indication.
AACE/ACE 2020 CPG specifies anabolic peptide therapy for very high fracture risk patients with very low BMD or recent fragility fracture or elevated FRAX probability.
Expect bone turnover marker monitoring at month 3 with P1NP rise as early biomarker.
Endocrine Society 2019 CPG anchors CTX and P1NP framework. P1NP rises significantly with PTH analog therapy as the early biomarker for treatment response.
Confirm sequential anti-resorptive therapy plan after anabolic course completion.
AACE/ACE 2020 CPG specifies bisphosphonate or denosumab maintenance after anabolic course to maintain bone density gains.
Confirm therapy duration limits per FDA labels.
Forteo and Tymlos generally limited to 24 months lifetime per FDA labels. Evenity generally limited to 12 monthly doses per FDA label.
Regulatory Context
The regulatory framework governing anabolic osteoporosis peptide therapy evolves continuously. FDA prescribing information for Forteo, Tymlos, and Evenity updates with each labeling cycle including new contraindications, monitoring specifications, and adverse event profile updates. AACE/ACE and Endocrine Society guidelines update periodically with accumulated post-marketing experience. The FDA cardiovascular boxed warning for Evenity issued April 2019 reflects post-marketing safety surveillance. The osteosarcoma boxed warning for Forteo and Tymlos reflects rodent toxicology data. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence.
Comparison
| Drug (FDA NDA) | Mechanism | Bone Turnover Pattern | Duration Limit + Boxed Warnings |
|---|---|---|---|
| Forteo (NDA 021318, teriparatide) | PTH 1-34 analog stimulates osteoblast formation | P1NP rises significantly; CTX rises moderately | Up to 24 months lifetime; osteosarcoma boxed warning |
| Tymlos (abaloparatide) | PTHrP analog stimulates osteoblast formation | P1NP rises significantly; CTX rises moderately | Up to 24 months lifetime; osteosarcoma boxed warning |
| Evenity (NDA 761062, romosozumab) | Sclerostin inhibitor dual-modulates bone | P1NP rises significantly; CTX decreases (unique signature) | 12 monthly doses; FDA cardiovascular boxed warning April 2019 |
| VERT trial 2001 | Teriparatide pivotal efficacy trial | 65% vertebral fracture reduction; 53% non-vertebral | 1,637 postmenopausal women, median 21 months follow-up |
| ACTIVE trial 2016 | Abaloparatide pivotal efficacy trial | 86% vertebral fracture reduction over 18 months | 2,463 postmenopausal women, 18 months follow-up |
| FRAME trial 2016 | Romosozumab pivotal efficacy trial vs placebo | 73% vertebral fracture reduction over 12 months | 7,180 postmenopausal women, 12 months follow-up |
| ARCH trial 2017 | Romosozumab + alendronate vs alendronate | 48% vertebral fracture reduction; CV safety signal | 4,093 postmenopausal women, 36 months; basis of CV boxed warning |
| Sequential framework | Anti-resorptive after anabolic course | Maintenance of bone density gains | Bisphosphonate or denosumab per AACE/ACE 2020 CPG |
Who This Applies To
- · Postmenopausal woman with high fracture risk osteoporosis preparing for Forteo or Tymlos.
- · Postmenopausal woman with very high fracture risk preparing for Evenity romosozumab therapy.
- · Man with high fracture risk osteoporosis preparing for teriparatide therapy where labeled.
- · Patient with glucocorticoid-induced osteoporosis preparing for Forteo per FDA label.
- · Patient with vitamin D deficiency requiring supplementation before bone-forming peptide initiation.
- · Patient with established cardiovascular disease evaluating Evenity per FDA boxed warning.
- · Patient completing anabolic peptide course preparing for sequential anti-resorptive maintenance.
- · Patient with primary hyperparathyroidism requiring endocrinology evaluation before therapy.
- · Patient considering DEXA bone mineral density and FRAX score for indication threshold.
- · Patient planning four-stage monitoring cadence with bone turnover marker tracking.
Verdict
Anabolic osteoporosis peptide therapy requires baseline calcium, vitamin D, PTH, creatinine, and bone turnover markers CTX and P1NP per FDA labels. The framework anchors in AACE/ACE 2020 and Endocrine Society 2019 CPGs. For Evenity, cardiovascular risk stratification adds per the FDA boxed warning April 2019. Baseline DEXA bone mineral density and FRAX fracture risk score establish indication threshold. P1NP rises significantly with teriparatide and abaloparatide as the early biomarker. Romosozumab uniquely dual-modulates bone with P1NP rise plus CTX decrease. Monitoring follows a four-stage cadence across the therapy course. Sequential anti-resorptive therapy applies after anabolic course completion.
In Plain Terms
Anabolic osteoporosis drugs include Forteo, Tymlos, and Evenity. Before starting any of these, your doctor orders calcium, vitamin D, parathyroid hormone, creatinine, and two bone markers called CTX and P1NP. The doctor also orders a DEXA scan to measure bone density. For Evenity, your cardiovascular history is reviewed because of the FDA boxed warning. Evenity is not used if you had a heart attack or stroke in the past year. Vitamin D supplementation is usually needed before starting. After the anabolic course ends, you transition to a maintenance drug.
Bone-building drugs like Forteo, Tymlos, and Evenity need careful bloodwork before starting. The doctor checks calcium, vitamin D, parathyroid hormone, kidney function, and two bone markers. A DEXA scan measures bone density. For Evenity specifically, your heart history matters because of an FDA warning. Vitamin D supplements are usually started first. After your course ends, you switch to a maintenance drug to keep the gains.
For anabolic osteoporosis peptide therapy, physician selection through state medical board license verification, ABMS board certification (endocrinology, rheumatology, or internal medicine with bone metabolism experience), and AMA Code 1.1.5 framework adherence is the legal and clinical gate. PSI maintains a vetted directory of practitioners ordering comprehensive osteoporosis peptide bloodwork per FDA prescribing information and AACE/ACE 2020 CPG.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Related Conditions
Related Education
Featured Compounds
Common Contexts
- · Postmenopausal woman with very high fracture risk preparing for Forteo or Tymlos PTH analog therapy
- · Postmenopausal woman with very high fracture risk preparing for Evenity romosozumab therapy
- · Man with high fracture risk osteoporosis preparing for teriparatide where FDA labeled
- · Patient with glucocorticoid-induced osteoporosis preparing for Forteo per FDA label indication
- · Patient evaluating sequential anti-resorptive transition after anabolic course completion
- · Patient with vitamin D deficiency requiring supplementation before bone-forming peptide initiation
- · Patient with established cardiovascular disease evaluating Evenity under FDA boxed warning framework
- · Patient with elevated PTH requiring primary hyperparathyroidism evaluation before anabolic therapy
- · Patient considering telehealth osteoporosis peptide consultation with external laboratory bloodwork
- · Patient planning four-stage monitoring cadence with bone turnover marker tracking
Important Context
This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for anabolic osteoporosis peptides including Forteo NDA 021318 (teriparatide), Tymlos (abaloparatide), and Evenity NDA 761062 (romosozumab with cardiovascular boxed warning), AACE/ACE 2020 Postmenopausal Osteoporosis CPG (Camacho et al.), Endocrine Society 2019 Pharmacological Management of Osteoporosis CPG (Eastell et al.), VERT trial (Neer et al. NEJM 2001), ACTIVE trial (Miller et al. JAMA 2016), FRAME trial (Cosman et al. NEJM 2016), ARCH trial (Saag et al. NEJM 2017), AMA Code of Medical Ethics 1.1.5 and 2.1.1, and FDA MedWatch adverse event reporting framework as referenced.
Your physician will order the specific baseline panel appropriate to the anabolic osteoporosis peptide, your fracture risk profile, your clinical context including cardiovascular history for Evenity contexts, and your prior bloodwork records. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions across primary care, endocrinology, rheumatology, cardiology, and other relevant specialties.
Self-ordering of bloodwork through direct-to-consumer laboratory services is not a substitute for physician-ordered baseline assessment with documented clinical interpretation. Quality clinical practice orders bloodwork in the context of the indication-specific evaluation including DEXA bone mineral density and FRAX fracture risk assessment.
Educational content only. Discuss with your physician before pursuing anabolic osteoporosis peptide therapy. Evenity carries an FDA cardiovascular boxed warning. PTH analog therapy with Forteo and Tymlos carries an osteosarcoma boxed warning. Therapy duration limits apply per FDA labels. Sequential anti-resorptive therapy is required after anabolic course completion per AACE/ACE 2020 CPG.
Sources and Citations
- [1] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
- [2] FDA Prescribing Information: Tymlos (abaloparatide) injection · 2022 · FDA NDA 208743 · Source
- [3] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
- [4] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (VERT trial) · New England Journal of Medicine · 2001 · DOI
- [5] Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis (ACTIVE trial) · JAMA · 2016 · DOI
- [6] Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME trial) · New England Journal of Medicine · 2016 · DOI
- [7] Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH trial) · New England Journal of Medicine · 2017 · DOI
- [8] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
- [9] Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline · Journal of Clinical Endocrinology and Metabolism · 2019 · DOI
- [10] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
- [11] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
- [12] WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis · World Health Organization Technical Report Series 843 · 1994 · Source
- [13] FRAX Fracture Risk Assessment Tool, University of Sheffield, WHO Collaborating Centre · University of Sheffield · 2024 · Source
- [14] FDA Cardiovascular Boxed Warning Communication: Evenity (romosozumab-aqqg) April 2019 · US Food and Drug Administration · 2019 · Source
- [15] FDA Compounding Quality Act of 2013: 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
- [16] FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program · US Food and Drug Administration · 2024 · Source
- [17] IOF-IFCC Bone Marker Standards Working Group: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment · Osteoporosis International · 2017 · DOI
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.